Gordon Wilkie, Ph.D., is the Vice President of Chemistry, Manufacturing and Controls (CMC) at Recludix Pharma. He was previously the head of CMC at Ribon Therapeutics, overseeing CMC activities across preclinical and clinical development for drug substance and drug product development, quality assurance, quality control, supply chain management, and regulatory. Prior to that, he was the Director of Process Chemistry Research and Development at Blueprint Medicines where he led the development and manufacturing of the active pharmaceutical ingredients (API) for the marketed drugs Ayvakit™ and Gavreto™. Earlier in his career, he was in process development at Forum Pharmaceuticals and spent close to a decade at Esai, Inc. where he was a member of the team that brought Halaven™ to market. Dr. Wilkie received his Ph.D. in Chemistry from The Scripps Research Institute and a B.A. in Chemistry from The Johns Hopkins University.
« Go Back